Serum 25(OH)D as a Biomarker for Cognitive Impairment in Parkinson Disease
Researchers sought to assess the relationship between serum 25(OH)D levels and cognition in patients with Parkinson disease.
Movement Disorders
Serum Urate Levels in Gout and Risk for Parkinson Disease in Older Adults
Researchers sought to assess whether serum urate possesses a neuroprotective effect against the risk for Parkinson disease in patients with gout.
Carbidopa-Levodopa and Motor Fluctuations in Parkinson Disease
Researchers sought to assess the time from levodopa/DCI initiation to the onset of motor fluctuations in patients with PD treated with levodopa/benserazide and levodopa/carbidopa.
Patients With Tourette Syndrome Susceptible to Assault, Committing Crimes
Researchers sought to establish whether patients with Tourette syndrome or chronic tic disorder are more likely to experience violent assault or be convicted of a crime.
Prevalence of Global Malnutrition in Children With Cerebral Palsy
In a systematic review and meta-analysis, researchers estimated the prevalence of malnutrition and nutritional deficiencies in children with cerebral palsy.
Elamipretide Gets Orphan Drug Status for Friedreich Ataxia
Elamipretide has been shown to improve frataxin levels in Friedreich ataxia patient-derived cells, and improve motor and cardiac function in an animal model of Friedreich ataxia.
Cognitive Problems Common Nonmotor Symptom in Patients With Cerebellar Ataxias
Presenting at the 2022 AAN Annual Meeting, researchers assessed the reported prevalence of nonmotor symptoms among adult patients with different types of progressive cerebellar ataxia.
Prediction of Parkinsonian Clinical State During Deep Brain Stimulation With AI
Presenting at the 2022 AAN Annual Meeting, researchers identified patient-specific spectral biomarkers of parkinsonian clinical state during deep brain stimulation using artificial intelligence.
Oligomeric Synuclein Tear Content Not a Marker for Parkinson Disease Stage
Presenting at the 2022 AAN Annual Meeting, researchers evaluated whether tear levels of oligomeric α-synuclein could differentiate between stages of Parkinson disease on the basis of disease duration.
β2-Adrenoreceptor Medications Associated With Lower Risk for Parkinson Disease
Presenting at the 2022 AAN Annual Meeting, researchers explored the association between β2-adrenoreceptor agonists and the risk for Parkinson disease.
- Loading...
Loading...
Next post in AAN 2022
Loading... 
Loading...